Trial Profile
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Tucatinib (Primary) ; Capecitabine; Trastuzumab; Trastuzumab
- Indications Advanced breast cancer; Carcinoma; HER2 positive breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms H2C; HER2CLIMB
- Sponsors Cascadian Therapeutics; Seagen
- 22 Feb 2023 According to Seagen media release, TUKYSA is now reimbursed in Ontario, Manitoba, Saskatchewan. The reimbursement is based on the data from this study.
- 06 Dec 2022 According to a Seagen media release, based on this trial TUKYSA is now authorized in British Columbia for reimbursement for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
- 10 Sep 2022 This trial has been completed in Austria, according to European Clinical Trials Database record.